COVID-19 vaccination and associated side effects: Addressing the global concern over vaccines for SARS-CoV-2 virus

The concern of side effects played a major part in vaccination hesitancy of the disease caused by the SARS-CoV-2 virus worldwide. This study not only tries to address the concern over vaccination side effects, but also projects various side effects and other associated factors. 1047 individuals participated in the present study. Chi square test was used to test significance of the model. Logistic regression was used to establish association between variables in terms of odds ratio. Of the total 83.23% males and 81.14% females who took Covishield vaccine, 80% females and 73.38 % males had systemic side effects after their first dose. Among those who took Covaxin vaccine, 70.71% females and 67.07% males have had systemic side effects after their first dose of vaccine for SARS-CoV-2 virus. After the second dose the percentage of those with systemic side effects decreases in both males (54.02% Covishield, 58.02% Covaxin) and females (61.35% Covishield, 68.42% Covaxin). The probability of having the systemic side effects of the first dose of vaccine for the SARS-CoV-2 virus significantly increases 1.578 times depending on the vaccine type/brand. The age of the individual also significantly increases the chances of having side effects after both the first (OR1.024, 95% CI) and the second dose (OR 1.015, 95% CI). The number of females having the side effect is significantly higher than the males after both the doses. The cases of systemic infections declined comparatively after the second dose of the same vaccine, whereas in published work it is the other way round. The reoccurrence of COVID-19 among the fully vaccinated individuals with Covaxin is comparatively higher than those with Covishield.